key: cord-0819805-rb8lxfmp
authors: Naik, H. B.; Alhusayen, R.; Frew, J.; Guilbault, S.; Hills, N. K.; Ingram, J. R.; Kudlinski, M. V.; Lowes, M. A.; Marzano, A. V.; Paul, M.; Villumsen, B.; Yannuzzi, C. A.
title: Biologic therapy is not associated with increased COVID-19 severity in Hidradenitis Suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry
date: 2021-09-16
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.09.016
sha: f3cd11decc94bc539dc5f3f72e2942d83e101182
doc_id: 819805
cord_uid: rb8lxfmp

nan

Despite sample size limitations, possible missed cases, and potential recall bias, this is the largest report of 106 COVID-19 outcomes in an international HS population. These data provide valuable information to guide 107 patient care during and post-pandemic. Asian 0 (0%) 1 (0.9%) 1 (0.7%) 1 (4.6%) 1 (4.6%) 2 (4.5%)

Hispanic 3 (12.0%) 13 (11.8%) 16 (11.8%) 3 (13.6%) 1 (4.6%) 4 (9.1%)

Mixed race 2 (8.0%) 8 (7.3%) 10 (7.4%) 0 (0%) 2 (9.1%) 2 (4.6%)

Other 0 (0%) 4 (3.7%) 4 (3.0%) 2 (9.1%) 3 (13.6%) 5 (11.4%)

United 

Global Hidradenitis Suppurativa COVID-19 Registry: a registry 112 to inform data-driven management practices

Moderate-to-severe hidradenitis 114 suppurativa under systemic therapy during the COVID-19 outbreak